Response to Yu et al. Article “Healthcare Resource Waste Associated with Patient Nonadherence and Early Discontinuation of Traditional Continuous Glucose Monitoring in Real-World Settings: A Multicountry Analysis”
Restricted accessLetterFirst published online September, 2018
Response to Yu et al. Article “Healthcare Resource Waste Associated with Patient Nonadherence and Early Discontinuation of Traditional Continuous Glucose Monitoring in Real-World Settings: A Multicountry Analysis”
YuS, VarugheseB, LiZ, KushnerPR: Healthcare resource waste associated with patient nonadherence and early discontinuation of traditional continuous glucose monitoring in real-world settings: a multicountry analysis. Diabetes Technol Ther, 2018; 20:420–427.
2.
BattelinoT, LiabatS, VeezeHJ, et al.: Routine use of continuous glucose monitoring in 10,501 people with diabetes mellitus. Diabet Med, 2015; 32:1568–1574.
3.
CohenO, KornerA, ChlupR, et al.: Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: prospective results from a community and academic practice patient registry. J Diabetes Sci Technol, 2009; 3:804–811.
4.
PicardS, HanaireH, Baillot-RudoniS, et al.: Evaluation of the adherence to continuous glucose monitoring in the management of type 1 diabetes patients on sensor-augmented pump therapy: the SENLOCOR study. Diabetes Technol Ther, 2016; 18:127–135.
5.
McQueenRB, EllisSL, MaahsDM, et al.: Frequency of CGM use and change in HbA1c for adults with type 1 diabetes in a clinical practice setting. Endocr Pract, 2014; 20:1007–1015.
6.
NørgaardET, ScaramuzzaA, BratinaN, et al.: Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther, 2013; 15:2013.
7.
WongJC, FosterNC, MaahsDM, et al.: Real-time continuous glucose monitoring among participants in the T1D Exchange Clinic Registry. Diabetes Care, 2014; 37:2702–2709.
8.
T1D Exchange: Why do some people with T1D stop using a pump and CGM?April20, 2016. https://t1dexchange.org/pages/why-do-some-people-with-t1d-stop-using-a-pumpand-cgm (accessed May4, 2017).
9.
PolonskyWH, HesslerD: Perceived accuracy in continuous glucose monitoring: understanding the impact on patients. J Diabetes Sci Technol, 2015; 9:330–341.
10.
de BockM, CooperM, RetterathA, et al.: Continuous glucose monitoring adherence: lessons from a clinical trial to predict outpatient behavior. J Diabetes Sci Technol, 2016; 10:627–632.
11.
LaffelLM, VolkeningLK, McmullenWJ, et al.: Improved CGM performance predicts CGM use and outcomes in pediatric patients with T1D. Presented at the American Diabetes Association 76th Scientific Sessions. June 10–14, 2016, New Orleans, LA. 163-LB.
12.
ChamberlainJ, DopitaD, GilgenE: Persistence of continuous glucose monitoring use in a community setting 1 year after purchase. Clin Diabetes, 2013; 31:106–109.
13.
T1D Exchange: Updates from the American Diabetes Association 78th Scientific Sessions.Presented at American Diabetes Association 78th Scientific Sessions, June 22–26, 2018, Orlando, FL.
14.
BeckRW, RiddlesworthT, RuedyK, et al.: Effect of continuous glucosemonitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA, 2017; 317:371–378.
15.
HeinemannL, DeissD, HermannsN, et al.: HypoDE: research design and methods of a randomized controlled study evaluating the impact of real-time CGM usage on the frequency of CGM glucose values <55 mg/dl in patients with type 1 diabetes and problematic hypoglycemia treated with multiple daily injections. J Diabetes Sci Technol, 2015; 9:651–662.
16.
LindM, PolonskyW, HirschIB, et al.: Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA, 2017; 317:379–387.
17.
BeckRW, RiddlesworthTD, RuedyKJ, et al.: Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol, 2017; 5:700–708.
18.
BeckRW, RiddlesworthTD, RuedyK: Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med, 2017; 167:365–374.
19.
ParkinCG, GrahamC, SmolskisJ: Continuous glucose monitoring use in type 1 diabetes: longitudinal analysis demonstrates meaningful improvements in HbA1c and reductions in health care utilization. J Diabetes Sci Technol, 2017; 11:522–528.
20.
BillingsL, ParkinCG, PriceD: Baseline HbA1c values predict the magnitude of glycemic improvement in patients with type 1 and type 2 diabetes: subgroup analyses from the diamond study program. Diabetes Technol Ther, 2018; 20:561–565.
21.
PawaskarM, IglayK, WittEA, et al.: Impact of the severity of hypoglycemia on health-related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes. J Diabetes Complications, 2018; 32:451–457.
22.
BrodM, ChristensenT, ThomsenTL, BushnellDM: The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health, 2011; 14:665–671.
23.
PrahaladP, AddalaA, BuckinghamB, et al.: Sustained continuous glucose monitor use in low-income youth with type 1 diabetes following insurance coverage supports expansion of continuous glucose monitor coverage for all. Diabetes Technol Ther, 2018; 20:632–634.
